Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
Yao, James C. , Guthrie, Katherine A. , Moran, César A. , Kulke, Matthew H. , Chan, Jennifer A. , LoConte, Noelle K. , Wolin, Edward M. , Mattar, Bassam, McDonough, Shannon, Blanke, Charles D. , Höchster, Howard S. , Moran, Cesar, LoConte, Noelle, McWilliams, Robert R. , Chen, Helen, Strosberg, Jonathan , Chen, Helen , LoConte, Noelle

Mayo Clinic

Journal of Clinical Oncology | April 6, 2017 | Volume: 35 | Issue: 15 | Pages: 1695-1703

10.1200/jco.2016.70.4072 | PMID 28384065 Get It

Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group system, enrolled patients with advanced grades 1 and 2 NETs with progressive disease or other poor prognostic features. Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week. The primary end point was centrally assessed PFS. This trial is registered with ClinicalTrials.gov as NCT00569127. Results A total of 427 patients was enrolled, of whom 214 were allocated to bevacizumab and 213 to IFN-α-2b. The median PFS by central review was 16.6 months (95% CI, 12.9 to 19.6 months) in the bevacizumab arm and was 15.4 months (95% CI, 9.6 to 18.6 months) in the IFN arm (hazard ratio [HR], 0.93; 95% CI, 0.73 to 1.18; P = .55). By site review, the median PFS times were 15.4 months (95% CI, 12.6 to 17.2 months) for bevacizumab and 10.6 months (95% CI, 8.5 to 14.4 months) for interferon (HR, 0.90; 95% CI, 0.72 to 1.12; P = .33). Time to treatment failure was longer with bevacizumab than with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003). Confirmed radiologic response rates were 12% (95% CI, 8% to 18%) for bevacizumab and 4% (95% CI, 2% to 8%) for IFN. Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%). Conclusion No significant differences in PFS were observed between the bevacizumab and IFN arms, which suggests that these agents have similar antitumor activity among patients with advanced NETs.
Associations between elevated pre‐treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma
Binder, Moritz , O’Byrne, Megan M., Ansell, Stephen, Feldman, Andrew L. , Novak, Anne J. , Porrata, Luis F. , Link, Brian K. , Witzig, T.E. , Maurer, Matthew J. , Cerhan, James R. , Markovic, Svetomir N. , Witzig, Thomas E. , Feldman, Andrew L , Link, Brian K , Binder, Moritz

Mayo Clinic

American Journal of Hematology | April 6, 2017 | Volume: 92 | Issue: 8 | Pages: 752-758

10.1002/ajh.24758 | PMID 28383112 Get It

AbstractHigher ratios of the pre‐treatment peripheral blood absolute lymphocyte (ALC) to absolute monocyte counts (AMC) are associated with improved outcomes in lymphoma. Conversely, elevated pre‐treatment serum cytokines are associated with inferior outcomes. The relationship between pre‐treatment serum cytokines and ALC/AMC ratios remains unknown. We studied twelve serum cytokines and the ALC/AMC ratios in 390 patients with untreated diffuse large B‐cell, follicular, mantle cell, T‐cell, and Hodgkin lymphoma. Different pre‐treatment serum cytokine concentrations correlated with ALC, AMC, and ALC/AMC ratios depending on the lymphoma type. In the entire cohort (n = 390) lower ALC/AMC ratios modestly correlated with higher IL‐2R (r = −0.36), IL‐12 (r = −0.17), IP‐10 (r = −0.23), and MIG (r = −0.32) concentrations (p < 0.001). Elevated IL‐2R was independently associated with suppressed ALC (OR 2.69, 95% CI 1.77–4.07,p < 0.001), elevated AMC (OR 2.05, 95% CI 1.34–3.14,p < 0.001), and suppressed ALC/AMC ratios (OR 3.51, 95% CI 2.31–5.34,p < 0.001). Both elevated IL‐2R (HR 2.27, 95% CI 1.48–3.49,p < 0.001) and suppressed ALC/AMC ratios (HR 1.53, 95% CI 1.03–2.28,p = 0.037) were independently associated with inferior overall survival. These data support the notion that elevated serum cytokines are immunosuppressive and provide further rationale to target the tumor microenvironment for therapeutic benefit.
Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Valla, Jon, Yaari, R. , Wolf, Andrew B. , Kusne, Yael , Beach, Thomas G. , Roher, Alex E., Corneveaux, Jason J., Huentelman, Matthew J. , Caselli, Richard J. , Reiman, Eric M.

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 22 | Issue: 1 | Pages: 307-313

10.3233/jad-2010-100129 | PMID 20847408 Get It

Cancer patient perspective on an anthology addressing end-of-life care: A qualitative study of The Art of Oncology, When the Tumor is Not the Target
Vickers, Kristin S. , Hathaway, Julie, Clark, Matthew M. , Britt, Teresa, Looker, Sherry, Johnson, P., Moynihan, Timothy J. , Loprinzi, Charles L. , Patten, Christi A.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 8208-8208

10.1200/jco.2004.22.90140.8208 Get It

Pilot evaluation of paroxetine for alleviation of hot flashes in men
Loprinzi, Charles L. , Barton, Debra L. , Sloan, Jeff A. , Novotny, Paul J. , Carpenter, Lisa A., Gettman, Matthew T., Christensen, Bradley J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 8016-8016

10.1200/jco.2004.22.90140.8016 Get It

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL)
Micallef, Ivana N. , Gayko, Urte, Cesano, Alessandra, Ansell, Stephen M. , Geyer, Susan M. , Inwards, David J. , Horning, Sandra J., Kahl, Brad S. , Maurer, Matthew J. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6580-6580

10.1200/jco.2004.22.90140.6580 Get It

Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors
Rao, Ravi D., Furth, Alfred, Mandrekar, Sumithra J. , Adjei, Alex A. , Ames, Matthew M. , Erlichman, Charles , Pitot, Henry C., Reid, Joel M. , Goetz, Matthew P. , Safgren, Stephanie L.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3053-3053

10.1200/jco.2004.22.90140.3053 Get It

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer
Erlichman, Charles , Toft, D O, Reid, J., Ames, M. M., Mandrekar, Sumithra J. , Ajei, A., McCollum, Andrea K., Ivy, Percy, Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3030-3030

10.1200/jco.2004.22.90140.3030 Get It

Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG)
Brown, Paul D. , Rummans, Teresa A. , Sloan, Jeff A. , Arusell, Robert M., Clark, Matthew M. , Buckner, Jan C. , Ballman, Karla V. , Maurer, Matthew J. , Boeve, Bradley F.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1524-1524

10.1200/jco.2004.22.90140.1524 Get It

NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM)
Buckner, Jan C. , Kreisberg, Jeffrey I., Boni, Joseph , James, C. David , Jenkins, Robert B. , Walsh, Daniel J. , Galanis, Evanthia , Maurer, Matthew J. , Ballman, Karla V. , Hidalgo, Manuel , Walsh, D. J.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 1503-1503

10.1200/jco.2004.22.90140.1503 Get It